X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs VENUS REMEDIES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA VENUS REMEDIES ASTRAZENECA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 87.3 -0.9 - View Chart
P/BV x 19.3 0.1 29,500.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
VENUS REMEDIES
Mar-18
ASTRAZENECA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,278126 1,015.1%   
Low Rs88361 1,444.5%   
Sales per share (Unadj.) Rs228.4301.8 75.7%  
Earnings per share (Unadj.) Rs10.4-24.9 -41.7%  
Cash flow per share (Unadj.) Rs16.32.5 639.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8293.3 33.7%  
Shares outstanding (eoy) m25.0012.34 202.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,526.7%   
Avg P/E ratio x104.2-3.8 -2,772.6%  
P/CF ratio (eoy) x66.436.7 180.8%  
Price / Book Value ratio x10.90.3 3,430.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,154 2,340.8%   
No. of employees `0001.40.9 146.6%   
Total wages/salary Rs m1,535393 390.6%   
Avg. sales/employee Rs Th4,210.94,026.1 104.6%   
Avg. wages/employee Rs Th1,132.2425.0 266.4%   
Avg. net profit/employee Rs Th191.1-331.8 -57.6%   
INCOME DATA
Net Sales Rs m5,7103,724 153.3%  
Other income Rs m12323 544.4%   
Total revenues Rs m5,8333,747 155.7%   
Gross profit Rs m463395 117.2%  
Depreciation Rs m147338 43.6%   
Interest Rs m0354 0.0%   
Profit before tax Rs m438-275 -159.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m17932 566.1%   
Profit after tax Rs m259-307 -84.4%  
Gross profit margin %8.110.6 76.5%  
Effective tax rate %40.8-11.5 -355.8%   
Net profit margin %4.5-8.2 -55.1%  
BALANCE SHEET DATA
Current assets Rs m3,2092,638 121.7%   
Current liabilities Rs m2,0702,305 89.8%   
Net working cap to sales %20.08.9 223.2%  
Current ratio x1.61.1 135.5%  
Inventory Days Days72135 53.4%  
Debtors Days Days3546 75.4%  
Net fixed assets Rs m7904,871 16.2%   
Share capital Rs m50123 40.5%   
"Free" reserves Rs m2,4193,496 69.2%   
Net worth Rs m2,4693,619 68.2%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m4,6057,509 61.3%  
Interest coverage xNM0.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.20.5 250.0%   
Return on assets %5.60.6 891.2%  
Return on equity %10.5-8.5 -123.7%  
Return on capital %17.71.6 1,121.2%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3000-   
Fx outflow Rs m2,015517 390.1%   
Net fx Rs m-1,715-517 332.1%   
CASH FLOW
From Operations Rs m88514 17.1%  
From Investments Rs m-94-123 76.0%  
From Financial Activity Rs mNA-387 0.0%  
Net Cashflow Rs m-64 -135.7%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 15.7 0.6 2,706.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   12,856 20,121 63.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; TCS and Bharti Airtel Top Gainers(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.7% while the Hang Seng is up 1.1%.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 19, 2019 11:37 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS